Fox Chase Cancer Center Recognized for Outstanding Achievement by ECOG-ACRIN Cancer Research Group

Dr. Edelman
Fox Chase Cancer Center was recently recognized by the ECOG-ACRIN Cancer Research Group for outstanding achievement in accrual, scientific contribution, and administrative participation.

PHILADELPHIA (January 9, 2024) — Fox Chase Cancer Center was recently recognized by the ECOG-ACRIN Cancer Research Group for outstanding achievement in accrual, scientific contribution, and administrative participation following an institutional research performance evaluation.

“Being recognized with this honor is truly a testament to the hard work the staff in our Office of Clinical Research put forth every day to facilitate and conduct all types of clinical trials,” said Martin Edelman, MD, Associate Cancer Center Director for Clinical Research Integration, as well as Professor and Chair of the Department of Hematology/Oncology at Fox Chase.

The Office of Clinical Research provides management, research support, and oversight for the conduct of cancer-related clinical trials for the center. Services are provided for all interventional treatment trials conducted within the center, including those at other campuses.

“This commendation from ECOG-ACRIN is an encouraging reminder that our efforts in clinical trial facilitation and development are excelling. We are proud to be recognized with this commendation and look forward to continued success in this area,” said Edelman.

Trials facilitated by the Office of Clinical Research can include those aimed at treatment, prevention, screening, diagnostics, quality of life, genetics studies, behavioral studies, and epidemiology or population-based studies. The office is responsible for institutional treatment trials developed by members of Fox Chase.

The ECOG-ACRIN Cancer Research Group is a multidisciplinary, membership-based scientific organization that designs and conducts cancer research for adults who have or are at risk of developing cancer. It is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health. Fox Chase has been a member of ECOG-ACRIN since 1971. Both ECOG-ACRIN and Fox Chase participate in the NCI’s National Clinical Trials Network.

ECOG-ACRIN conducts performance evaluations each year to ensure that its members meet rigorous standards to conduct cancer research with and through the group. This includes a formal audit and quality control assessment. Its members include nearly 140 hospital networks and programs, encompassing nearly 1,500 individual cancer centers and hospitals in total. Fox Chase was among 46 programs that received special commendations.

The evaluations are conducted by ECOG-ACRIN senior administrative staff and a subset of the Principal Investigator Committee, which is additionally tasked with setting group policy, approving new members and principal investigators at member institutions, and approving changes to the organization’s constitution when necessary.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427